Adempas and Hot flush - a phase IV clinical study of FDA data

Summary:

Hot flush is reported as a side effect among people who take Adempas (riociguat), especially for people who are 60+ old, have been taking the drug for 1 - 6 months also take Opsumit, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Hot flush when taking Adempas. It is created by eHealthMe based on reports of 29,726 people who have side effects when taking Adempas from the FDA, and is updated regularly.

What is Adempas?

Adempas has active ingredients of riociguat. eHealthMe is studying from 29,741 Adempas users. Check the latest studies of Adempas.

What is Hot flush?

Hot flush (sudden feelings of heat) is found to be associated with 1,769 drugs and 2,342 conditions by eHealthMe. Check the latest studies of Hot flush.

On Jul, 12, 2026

29,726 people reported to have side effects when taking Adempas.
Among them, 177 people (0.6%) have Hot flush.

Among these 177 people:

* Approximation only. Some reports may have incomplete information.

Do you take Adempas and have Hot flush?

- Check whether Hot flush is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adempas:

Adempas (29,741 reports)

Hot flush treatments and more:

Hot flush (91,208 reports)

How severe was Hot flush and when was it recovered:

Hot flush in Adempas

Expand to all the drugs that have ingredients of riociguat:

Hot flush and drugs with ingredients of riociguat (197 reports)

Sub-studies by age:

0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Adempas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hot flush:

Hot flush (1,769 drugs)

Browse all the conditions that are associated with Hot flush:

Hot flush (2,342 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on riociguat (the active ingredients of Adempas) and Adempas (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.